IL111601A0 - Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna - Google Patents

Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna

Info

Publication number
IL111601A0
IL111601A0 IL11160194A IL11160194A IL111601A0 IL 111601 A0 IL111601 A0 IL 111601A0 IL 11160194 A IL11160194 A IL 11160194A IL 11160194 A IL11160194 A IL 11160194A IL 111601 A0 IL111601 A0 IL 111601A0
Authority
IL
Israel
Prior art keywords
dna
rna
conjugate
vector
encoding
Prior art date
Application number
IL11160194A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL111601A0 publication Critical patent/IL111601A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
IL11160194A 1993-11-12 1994-11-11 Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna IL111601A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939323429A GB9323429D0 (en) 1993-11-12 1993-11-12 Therapy

Publications (1)

Publication Number Publication Date
IL111601A0 true IL111601A0 (en) 1995-01-24

Family

ID=10745113

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11160194A IL111601A0 (en) 1993-11-12 1994-11-11 Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna

Country Status (15)

Country Link
US (2) US6140100A (fr)
EP (1) EP0728018B1 (fr)
JP (1) JPH09507834A (fr)
AT (1) ATE246516T1 (fr)
AU (1) AU688412B2 (fr)
CA (1) CA2176024A1 (fr)
DE (1) DE69433015T2 (fr)
DK (1) DK0728018T3 (fr)
ES (1) ES2204935T3 (fr)
GB (1) GB9323429D0 (fr)
IL (1) IL111601A0 (fr)
MY (1) MY114140A (fr)
NZ (1) NZ276137A (fr)
WO (1) WO1995013095A2 (fr)
ZA (1) ZA948987B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB2309033B (en) * 1994-12-23 1999-06-02 Zeneca Ltd Chemical compounds
HUT77450A (hu) * 1994-12-23 1998-04-28 Zeneca Ltd. Kémiai vegyületek
HUP9900062A3 (en) * 1995-08-16 1999-11-29 Zeneca Ltd Chemical compounds
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
WO1999033870A2 (fr) * 1997-12-31 1999-07-08 Incyte Pharmaceuticals, Inc. Proteines humaines regulatrices
AU783948B2 (en) * 1999-11-12 2006-01-05 Lexicon Genetics Incorporated Novel human proteases and polynucleotides encoding the same
WO2002049672A2 (fr) * 2000-12-21 2002-06-27 Mcgill University Compose utilise pour cibler des cellules specifiques a toxicite systemique reduite
CN103288793B (zh) 2001-09-14 2015-09-23 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
NZ537690A (en) 2002-07-15 2009-07-31 Univ Texas Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
EP1725250A2 (fr) * 2004-02-18 2006-11-29 Frutarom Ltd. Procede de preparation de conjugues peptides/oligonucleotides
SI1794294T1 (sl) * 2004-09-27 2011-11-30 Sanofi Aventis Deutschland Rekombinantna karboksipeptidaza B
US20060167057A1 (en) * 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
DK2219672T3 (en) 2007-11-09 2016-05-17 Peregrine Pharmaceuticals Inc The anti-VEGF antibody compositions and methods
PL2491788T3 (pl) 2011-02-25 2016-07-29 Kraft Foods R & D Inc Wyrób spożywczy z formowanym korpusem
US9340504B2 (en) * 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
MY183427A (en) * 2013-12-17 2021-02-18 Stella Pharma Corp A method for producing 2-fluoro-4-borono-l-phenylalanine, and precursor of 2-fluoro-4-borono-l-phenylalanine
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
WO2020032951A1 (fr) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Conjugués d'enzymes antipaludiques, kits les contenant, et procédés de production et d'utilisation associés
WO2022272307A1 (fr) * 2021-06-24 2022-12-29 Lycia Therapeutics, Inc. Composés bifonctionnels de liaison au récepteur des folates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
US6140100A (en) 2000-10-31
CA2176024A1 (fr) 1995-05-18
WO1995013095A2 (fr) 1995-05-18
ZA948987B (en) 1996-05-13
MY114140A (en) 2002-08-30
AU688412B2 (en) 1998-03-12
JPH09507834A (ja) 1997-08-12
DE69433015D1 (de) 2003-09-11
DK0728018T3 (da) 2003-11-24
US6319702B1 (en) 2001-11-20
NZ276137A (en) 1998-04-27
ES2204935T3 (es) 2004-05-01
GB9323429D0 (en) 1994-01-05
WO1995013095A3 (fr) 1995-07-13
ATE246516T1 (de) 2003-08-15
AU8148894A (en) 1995-05-29
EP0728018A1 (fr) 1996-08-28
EP0728018B1 (fr) 2003-08-06
DE69433015T2 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
IL111601A0 (en) Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna
CA2205382A1 (fr) Molecules d'adn enzymatiques
EP1108724A3 (fr) Synthèse de methoxy nucléosides et de molécules d'acide nucléique enzymatique
AU4526193A (en) Binding competent oligomers containing 2', 5' linkages
EP0804609A4 (fr) NOUVEAUX GENES DE REPONSE p53
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
WO2001079463A3 (fr) Acides nucleiques codant pour des polypeptides ayant une activite haloperoxydase
IL123667A0 (en) Pneumococcal genes portions thereof expression products therefrom and uses of such genes portions and products
AU2434195A (en) Thymidine kinase mutants
EP1012603A4 (fr) Fragments fonctionnels de la proteine vpr vih-1 et procedes d'utilisation
WO2000053776A3 (fr) Nouveaux genes humains du type kallikreine
AUPP472398A0 (en) Protease susceptibility II
HUT75717A (en) Nucleic acid molecules encoding cytoplasmatic alcohol dehydrogenase and glutamil-cystein synthetase, vectors to introduce them and processes employing these vectors
AU6724794A (en) GRB3-3 gene, its variants and their uses
MX9703364A (es) Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso.
IL117194A0 (en) Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them
ZA97835B (en) Purified sr-p70 protein
WO1996015240A3 (fr) Analogues de ribozymes
EP0643719A4 (fr) Sequences d'acides nucleique codant pour des sequences d'acides nucleiques qui codent pour le recepteur de l'interleukine-9, ou complementaires a ces sequences.
EP1047710B1 (fr) Gene orotidine-5'-phosphate decarboxylase, produit de synthese genique contenant ce gene et son utilisation
CA2287902A1 (fr) Molecules d'acides nucleiques isolees codant des membres de la famille ssx et utilisations de ces molecules
AU782261C (en) Novel glycosyltransferase genes
WO1992011367A3 (fr) Recepteurs lipidiques de micro-organismes et adhesines correspondantes, sequences d'adn codant des adhesines et utilisation desdites adhesines
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
PL321890A1 (en) Variants human dnase i